Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
By Alexandria Carolan
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation
- Leading a Comprehensive Cancer Center—one job or two?
- Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week - Rathmell: To improve funding outlook, we must reverse distrust in science